Covenant High Plains Surgery Center

First and only free-standing ambulatory surgery center in West Texas to perform robot-assisted total knee replacement surgery using the state-of-the-art Stryker MAKO® surgical robot

West Texas patients seeking outpatient knee replacement surgery have a new, high-quality, cost-effective choice for their care at a nationally accredited center that meets the highest standards for patient safety and quality.

Dr. David Shephard announced today the successful completion of West Texas first outpatient robot-assisted knee replacement surgery at a free-standing ambulatory surgery center (ASC) using the Stryker MAKO® surgical robot.

Dr. Shephard is a Johns Hopkins fellowship-trained and board-certified orthopedic surgeon, and a partner at Lubbock Sports Medicine. He has performed more than a thousand robot-assisted knee replacements at Covenant Medical Center and Grace Surgical Hospital and welcomed the opportunity to extend this treatment option to a completely new environment.

“For appropriate candidates, an ASC is a safe, convenient, and cost-effective option, and we are proud to be the first center in West Texas to offer patients this choice,” stated Dr. Shephard. “Patients who undergo robot-assisted total knee replacement at our center will often go home the same day, at most the next morning. Studies show that recovery at home can be beneficial to the patient, speeding the healing process, and reducing the risk of infection.”

The Ambulatory Surgery Center Association notes that “ASCs have transformed the outpatient experience for millions of Americans by providing them with a more convenient alternative to hospital-based outpatient procedures—and done so with a strong track record of quality care and positive patient outcomes,” and ASCs save Medicare and patients billions of dollars each year by offering excellent care at lower overall costs.

“The Stryker MAKO® robotic platform was selected because of its strong track record of proven results,” stated CHPSC Administrator Alfonso del Granado. “And now, for the first time, patients in West Texas have the option to benefit from this innovative technology in an ambulatory surgery center. Too often, patients have not been able to afford the treatment options available at large hospitals. With this new program, we are demonstrating our commitment to offer patients the best care in West Texas.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version